Paradigmia
⌕Sign in ↗
Lessons

Complement regulatory proteins and the regulatory process (II)

Created by: Alfredo Corell

Explanation of the table:

There are soluble regulatory proteins (synthesised by human cells and released into the surrounding medium) and others that are bound to the membrane. The following stand out:

  • C1 inhibitor (found in all cells of the body except platelets) is important in starting up the system (in the classical pathway). It is a serine protease inhibitor that binds covalently to C1r and C1s, blocking their ability to take part in the classical pathway. It can also act in the lectin pathway, as it can bind to and block MASP. Disease: hereditary angioneurotic oedema.
  • Factor H: acts in the alternative pathway by accelerating the breakdown of the C3 convertase (C3bBb) of the alternative pathway. It acts as a cofactor for the proteolysis of C3b by factor I.
  • Protein S (vitronectin): is terminal. It binds to the C5b-C7 complex and prevents insertion of the MAC into the membrane. Clusterin has the same function.
  • C4bBP takes part in the classical and lectin pathways by degrading C3 convertase, for which it needs other cofactors.
  • Factor I: inactivates all three pathways through proteolytic cleavage of C4b and C3b, together with other cofactors.

The membrane-bound molecules are:

  • CR1: takes part in all pathways by dissociating C3 convertase.
  • MCP (CD46): in all pathways. It acts as a cofactor in the proteolysis of C4b and C3b by factor I, in many tissues. It inhibits lysis of the body’s own cells.
  • DAF (CD55): accelerates the dissociation of C3 convertase (once the convertase has formed) in all pathways. Wide tissue distribution. It inhibits destruction of the body’s own cells.
  • Protectin (CD59): terminal, with wide tissue distribution. It inhibits lysis of the body’s own cells. They block the binding of C8 to C9, preventing the MAC from attaching to the body’s own membranes and causing their subsequent lysis. They are restricted to C8 and C9 of the same species.

The process of complement regulation

There are three stages:

1. Before the formation of C3 convertase

  • C1 inhibitor is the main player; it causes the dissociation of C1q.
  • Classical pathway: the type I receptor (CR1), the cofactor MCP and C4bBP act, blocking the binding of C4b to C2a and so preventing the formation of C3 convertase. Factor I then acts (it requires the collaboration of the preceding factors) and cleaves the structure, blocking the classical pathway.
  • Alternative pathway: CR1 (CD35), MCP (CD46) and factor H act and prevent the binding of C3b to factor B. Factor I then acts and degrades C3b into C3f and iC3b (which is degraded again by the same factor into C3c and C3dg).

2. After C3 convertase

  • C4bBP, CR1, factor H and DAF (CD55) are involved, dissociating C3 convertase once it has formed.

3. Regulation of the formation of the membrane attack complex (MAC) or of its attachment to the cell surface.

  • Protein S (vitronectin) blocks the lytic phase by preventing the insertion of C5b-C7 into the membrane (+ clusterin).
  • Protectin (CD59), also called homologous restriction factor (HRF) or MIRL, acts by inhibiting the binding of C8 to C9, so that the latter does not polymerise and no pore is formed.

Your study

Select a passage in the lesson. Your highlights are private.

0Back to course →
Keep exploring

Knowledge does not end here.

Paradigmia · YouTube ↗